Ubelgiji - Kiingereza - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

orifarm a.s. - sodium risedronate 35 mg - eq. risedronic acid 32,5 mg - film-coated tablet - risedronic acid

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

theramex australia pty ltd - risedronate sodium -

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - risedronate sodium; calcium carbonate; colecalciferol -

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

warner chilcott uk limited - risedronate sodium ; calcium carbonate; colecalciferol - granules effervescent - 35 + 1000/880 iu milligram - risedronic acid, calcium and colecalciferol, sequential

Singapoo - Kiingereza - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - risedronate sodium - tablet, film coated - 30 mg

Uingereza - Kiingereza - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - risedronate sodium - oral tablet - 35mg

Marekani - Kiingereza - NLM (National Library of Medicine)

impax generics - risedronate sodium hemi-pentahydrate (unii: hu2yaq274o) (risedronic acid - unii:km2z91756z) - risedronate sodium delayed-release tablets are indicated for the treatment of osteoporosis in postmenopausal women. in postmenopausal women, risedronate sodium has been shown to reduce the incidence of vertebral fractures and a composite endpoint of nonvertebral osteoporosis-related fractures [see clinical  studies (14.1) ]. the optimal duration of use has not been determined. the safety and effectiveness of risedronate sodium delayed-release tablets for the treatment of osteoporosis are based on clinical data of one year duration. all patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. patients at low-risk for fracture should be considered for drug discontinuation after 3 to 5 years of use. patients who discontinue therapy should have their risk for fracture re-evaluated periodically. risedronate sodium delayed-release tablets are contraindicated in patients with the following conditions: - abnormalities of the esophagus which delay esophageal emp

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

imed healthcare ltd. - risedronate sodium - coated tablets - 35 milligram

Uingereza - Kiingereza - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - risedronate sodium - oral tablet - 5mg

Uingereza - Kiingereza - MHRA (Medicines & Healthcare Products Regulatory Agency)

dowelhurst ltd - risedronate sodium - oral tablet - 5mg